Daily hemodialysis stops the progression of cardiac hypertrophy in uremic patients and reverts it toward normality by improving blood pressure control.
Cardiac hypertrophy, a well-known independent risk factor for cardiovascular death, is a very frequent complication in ESRD patients. Its frequency tends to be even higher in dialyzed patients due to the fact that the current dialytic treatments are unable to keep under a satisfactory control the various responsible factors and particularly the blood pressure, which is largely the most important. Daily hemodialysis, a more frequent schedule consisting of 6-7 sessions/week lasting 2 or more hours, has definitely proved its superiority in controlling blood pressure and in improving anemia, and thus has the requisites for positively influencing cardiac hypertrophy. In fact, a series of studies, both retrospective and prospective, performed during the last years by our group, have confirmed that this new, more frequent and thus more physiological schedule, is able not only to stop the progression of the cardiac hypertrophy in uremic patients but also to revert toward the normality, in a relatively short time. This appears to be essentially a consequence of the excellent blood pressure control, which in turn derives from the easier control of the true dry weight, achievable with this type of dialytic treatment.
Buoncristianí et al. (Fri,) conducted a review in End-stage renal disease (ESRD) with cardiac hypertrophy. Daily hemodialysis vs. Standard dialytic treatments was evaluated on Progression of cardiac hypertrophy. Daily hemodialysis stops the progression of cardiac hypertrophy in uremic patients and reverts it toward normality by improving blood pressure control.